scholarly journals Circulating levels of catestatin are significantly higher in heart failure patients with ischemic vs. non-ischemic cardiomyopathy: the role of catestatin as a compensatory marker of neurohumoral activation

2018 ◽  
Vol 13 (11-12) ◽  
pp. 350-351
Author(s):  
Josip Anđelo Borovac ◽  
Joško Božić ◽  
Daniela Šupe Domić ◽  
Zora Sušilović Grabovac ◽  
Duška Glavaš
Keyword(s):  
Heart Failure ◽  
Ischemic Cardiomyopathy ◽  
Heart Failure Patients ◽  
Neurohumoral Activation ◽  
Circulating Levels

Galectin-3 in Heart Failure – Linking Fibrosis, Remodelling and Progression

2010 ◽  
Vol 6 (2) ◽  
pp. 33 ◽  
Author(s):  
Christopher R deFilippi ◽  
G Michael Felker ◽  
◽  
Keyword(s):  
Heart Failure ◽  
Ejection Fraction ◽  
Risk Stratification ◽  
Cardiac Fibrosis ◽  
The Elderly ◽  
Preserved Ejection Fraction ◽  
Heart Failure Patients ◽  
Large Populations ◽  
Galectin 3

For many with heart failure, including the elderly and those with a preserved ejection fraction, both risk stratification and treatment are challenging. For these large populations and others there is increasing recognition of the role of cardiac fibrosis in the pathophysiology of heart failure. Galectin-3 is a novel biomarker of fibrosis and cardiac remodelling that represents an intriguing link between inflammation and fibrosis. In this article we review the biology of galectin-3, recent clinical research and its application in the management of heart failure patients.

Twin peaks diversity with sacubitril/valsartan treatment responses in cardiomyopathic heart failure patients of non-ischemic compared to ischemic etiologies

2020 ◽  
Vol 41 (Supplement_2) ◽  
Author(s):  
H.Y Chang ◽  
W.R Chiou ◽  
P.L Lin ◽  
C.Y Hsu ◽  
C.T Liao ◽  
...  
Keyword(s):  
Heart Failure ◽  
Primary Endpoint ◽  
Ischemic Cardiomyopathy ◽  
Ventricular Remodeling ◽  
Left Ventricular Ejection ◽  
Funding Source ◽  
Heart Failure Patients ◽  
Twin Peaks ◽  
All Cause Mortality

Abstract Background Ischemic cardiomyopathy (ICM) has been associated with increased mortality when compared with non-ischemic cardiomyopathy (NICM) from several heart failure (HF) cohorts. Instead, PARADIGM study demonstrated similar event rates of cardiovascular (CV) death, all-cause mortality and HF readmissions between ICM and NICM patients. Although the beneficiary effect of sacubitril/valsartan (SAC/VAL) compared to enalapril on these endpoints was consistent across etiologic categories, PARADIGM study did not analyze the effect of ventricular remodeling of SAC/VAL on patients with different HF etiologies, which may significantly affect treatment outcomes. Purpose We aim to compare alterations of left ventricular ejection fraction (LVEF) following SAC/VAL treatment and its association with clinical outcomes in patients with different HF etiologies. Methods Treatment with angiotensin receptor neprilysin inhibitor for Taiwan heart failure patients (TAROT-HF) study is a multicenter study which enrolled 1552 patients with LVEF <40%, whom had been on SAC/VAL treatment from 9 hospitals between 2017 and 2018. After excluding patients without having follow-up echocardiographic studies, patients were grouped by HF etiologies and by LVEF changes following treatment for 8-month period. LVEF improvement ≥15% was defined as “significant improvement”, 5–15% as “marginal improvement”, and <5% or worse as “lack of improvement”. The primary endpoint was a composite of CV death or a first hospitalization for HF. Mean follow-up period was 726 days. Results A total of 1230 patients were analyzed. Patients with ICM were significantly older, more male, and prone to have associated hypertension and diabetes. On the other hand, patients with NICM had lower LVEF and higher likelihood of atrial fibrillation. LVEF increase was significantly greater in patients with NICM compared to those with ICM (11.2±12.4% vs. 6.9±9.8, p<0.001). The effect of ventricular remodeling of SAC/VAL on patients with NICM showed twin peaks diversity (Significant improvement 37.1%, lack of improvement 42.3%), whereas in patients with ICM the proportions of significant, marginal and lack of improvement groups were 19.4%, 28.2% and 52.4%, respectively. The primary endpoint showed twin peaks diversity also in patients with NICM in line with LVEF changes: adjusted HR for patients with NICM and significant improvement was 0.41 (95% CI 0.29–0.57, p<0.001), for patients with NICM and lack of improvement was 1.54 (95% CI 1.22–1.94, p<0.001). Analyses for CV death, all-cause mortality, and HF readmission demonstrated consistent results. Conclusion Patients with NICM had higher degree of LVEF improvement than those with ICM following SAC/VAL treatment, and significant improvement of LVEF in NICM patients may indicate favorable outcome. NICM patients without response to SAC/VAL treatment should serve as an indicator for poor clinical outcome and warranted meticulous HF management. Funding Acknowledgement Type of funding source: Private hospital(s). Main funding source(s): Cheng Hsin General Hospital

scholarly journals What will be the role of I-123 MIBG in improving the outcome of medically treated heart failure patients?

2012 ◽  
Vol 19 (6) ◽  
pp. 1198-1205 ◽  
Author(s):  
Fahad Waqar ◽  
Stephanie H. Dunlap ◽  
Myron C. Gerson
Keyword(s):  
Heart Failure ◽  
Heart Failure Patients

scholarly journals PROGNOSTIC ROLE OF ATRIAL FIBRILLATION AND HEART RATE CONTROL IN CHRONIC HEART FAILURE PATIENTS

2013 ◽  
Vol 61 (10) ◽  
pp. E735
Author(s):  
Savina Nodari ◽  
Marco Triggiani ◽  
Laura Lupi ◽  
Alessandra Manerba ◽  
Giuseppe Milesi ◽  
...  
Keyword(s):  
Heart Failure ◽  
Atrial Fibrillation ◽  
Heart Rate ◽  
Chronic Heart Failure ◽  
Rate Control ◽  
Heart Rate Control ◽  
Prognostic Role ◽  
Heart Failure Patients

scholarly journals Pathophysiology of exercise intolerance in chronic diseases: the role of diminished cardiac performance in mitochondrial and heart failure patients

Open Heart ◽  
2017 ◽  
Vol 4 (2) ◽  
pp. e000632 ◽  
Author(s):  
Jodi McCoy ◽  
Matthew Bates ◽  
Christopher Eggett ◽  
Mario Siervo ◽  
Sophie Cassidy ◽  
...  
Keyword(s):  
Heart Failure ◽  
Chronic Diseases ◽  
Cardiac Performance ◽  
Exercise Intolerance ◽  
Heart Failure Patients

scholarly journals Clinical Presentation of Heart Failure Patients Admitted in National Institute of Cardiovascular Diseases, Dhaka

2014 ◽  
Vol 15 (1) ◽  
pp. 18-22
Author(s):  
Md. Toufiqur Rahman ◽  
A A S Majumder ◽  
Afzalur Rahman ◽  
Abdul Wadud Chowdhury
Keyword(s):  
Heart Failure ◽  
Cardiovascular Diseases ◽  
Ischemic Cardiomyopathy ◽  
Clinical Presentation ◽  
The United States ◽  
Age Group ◽  
Socioeconomic Condition ◽  
Heart Failure Patients ◽  
Coronary Syndrome ◽  
Incident Cases

Background: Heart failure is a complex clinical syndrome that arises secondary to abnormalities of cardiac structure and/or function (inherited or acquired) that impair the ability of the left ventricle to fill or eject blood. The worldwide prevalence and incidence rates of heart failure (HF) are approaching epidemic proportions, as evidenced by the relentless increase in the number of HF hospitalizations, the growing number of HF-attributable deaths, and the spiraling costs associated with the care of HF patients. Worldwide, HF affects nearly 23 million people. In the United States, HF affects approximately 4.7 million persons (1.5 to 2 percent of the total population), with approximately 550,000 incident cases of HF diagnosed annually. Heart failure patients have various presentations and different etiologies. So, this study aimed to see the different clinical presentations of hospitalized heart failure patients. Methods: This study was done to see Clinical Presentation of Heart Failure Patients admitted in National Institute of Cardiovascular Diseases, Dhaka. Total 2112 patients were enrolled for this study during the period of August 2006 to July 2011. Results: Most of the patients (65%) were of 51-70 years age group. 75% (1584) patients were male. 98% patients presented with SOB, 95% patients had basal crepitation, 74% had orthopnoea, 59% had Paroxysmal Nocturnal Dyspoea (PND), 40% had leg edema and 25% had raised JVP. Average heart rate was 85 beats/min, average systolic B.P. was 118 mm Hg and average diastolic B.P. was 73 mm Hg. 45% population had hypertension, 29% patients had diabetes and 27% had concomitant respiratory illness. Average EF was 38%. Ischemic Cardiomyopathy was the commonest (39%) cause of heart failure, acute coronary syndrome was the second leading (29%) cause and valvular heart disease is the third common cause.Conclusion: Most of the heart failure patients are elderly age group. Most of the patients presented with shortness of breath and bilateral basal creps. Most patients had co-morbid other illness that influences the natural course of heart failure patients. Most common causes are ischemic cardiomyopathy, a sequel of ischemic insult of the heart. So, patients of acute or chronic ischemic heart diseases should be treated and follow up with care, considering their socioeconomic condition also. DOI: http://dx.doi.org/10.3329/jom.v15i1.19854 J Medicine 2014; 15: 18-22

Sign in / Sign up

Export Citation Format

Share Document